Vireo Growth Q2 Revenue Soars 335% to $209M, Nears Breakeven
VREOF sits 21% above its 52-week low of $8.91.
Summary
Vireo Growth's Q2 2026 revenue jumped 335% to $209.3M, nearly reaching breakeven with a $0.1M net loss. Adjusted EBITDA hit $41.5M. The company also secured a new $85M credit facility and has multiple acquisitions pending.
Key Events · Earnings and Guidance · VREOF
-
Revenue Surges 335%
Q2 2026 revenue reached $209.3 million, up from $48.1 million in Q2 2025, driven by acquisitions of Eaze, Vireo Health of Rocky Mountain, Hawthorne, and Bridgewell.
-
Near Breakeven Net Loss
Net loss narrowed to $0.1 million in Q2 2026 from $14.9 million a year ago, reflecting improved gross margins and a $21.7 million bargain purchase gain from the Hawthorne acquisition.
-
Adjusted EBITDA Positive
Adjusted EBITDA was $41.5 million for Q2 2026, compared to $13.3 million in Q2 2025, indicating strong underlying operational performance.
-
Balance Sheet Expansion
Total assets grew to $1,273.7 million from $817.2 million at year-end 2025, while total liabilities increased to $831.2 million from $509.8 million, reflecting acquisition financing.
Analysis · VREOF · Life Sciences
A transformative quarter for Vireo Growth, with revenue surging 335% year-over-year to $209.3 million, driven by aggressive M&A. The company nearly broke even with a net loss of just $0.1 million, a dramatic improvement from the $14.9 million loss a year ago. Adjusted EBITDA turned strongly positive at $41.5 million. The balance sheet expanded massively, with total assets more than doubling to $1.27 billion, funded by a mix of debt and equity. The company also disclosed a new $85 million credit facility and several pending acquisitions, signaling continued aggressive expansion. This is a major inflection point for the company's financial trajectory.
At the time of this filing, VREOF was trading at $10.80 on OTC in the Life Sciences sector, with a market capitalization of approximately $532.5M. The 52-week trading range was $8.91 to $24.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.